Zentalis director files Form 3 with no trades

Zentalis Pharmaceuticals, Inc. director Campbell Shannon filed an initial Form 3 insider ownership report.

Rhea-AI Filing Summary

Zentalis Pharmaceuticals, Inc. director Campbell Shannon filed an initial Form 3 insider ownership report. The excerpt shows no reported transactions, no derivative positions, and no holding entries, indicating that this filing is purely administrative disclosure of insider status without visible trading activity.

Key Terms

Form 3, insider, derivative positions

3 terms

Form 3 regulatory

"Campbell Shannon filed an initial Form 3 insider ownership report."

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

insider regulatory

"filed an initial Form 3 insider ownership report."

derivative positions financial

"no reported transactions, no derivative positions, and no holding entries"

Derivative positions are contracts that derive their value from an underlying asset—such as a stock, bond, currency or commodity—and include instruments like options, futures and swaps. Think of them as bets or insurance tied to an asset’s future price: they let investors amplify returns, hedge risk or take exposure without owning the asset directly, which can meaningfully increase potential gains, losses and volatility in a portfolio.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the ZNTL Form 3 filed by Campbell Shannon show?

The Form 3 for Zentalis Pharmaceuticals, Inc. reports director Campbell Shannon as a new insider. The excerpt shows no reported share transactions, no derivative positions, and no holding entries, making this a routine administrative disclosure of insider status.

Are there any share purchases or sales in the ZNTL Form 3 for Campbell Shannon?

No share purchases or sales appear in this Zentalis Pharmaceuticals, Inc. Form 3 excerpt. The transactions section is empty and transactionSummary shows zero buy, sell, acquire, dispose, and exercise activity, indicating no trading is reported here.

Does the ZNTL Form 3 show any option or derivative holdings for Campbell Shannon?

The Form 3 excerpt shows no derivative holdings for Campbell Shannon at Zentalis Pharmaceuticals, Inc. The derivativeSummary is empty and derivativeTransactionCount is zero, so no options, warrants, or other derivatives are listed in this data.

Is the ZNTL Form 3 for Campbell Shannon a routine insider filing?

Yes, this appears to be a routine initial insider ownership filing for Zentalis Pharmaceuticals, Inc. It identifies Campbell Shannon as a director and, in the provided data, includes no transactions, holdings, or derivatives, indicating an administrative disclosure only.

What is the role of Campbell Shannon in Zentalis Pharmaceuticals, Inc. according to the Form 3?

According to the Form 3 data, Campbell Shannon is a director of Zentalis Pharmaceuticals, Inc. The is_director flag is marked, while officer and ten percent owner indicators are not, so the filing reflects board-level insider status without officer designation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/27/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Campbell Shannon

(Last) (First) (Middle)

C/O ZENTALIS PHARMACEUTICALS, INC.

10275 SCIENCE CENTER DRIVE, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/22/2026

3. Issuer Name and Ticker or Trading Symbol
Zentalis Pharmaceuticals, Inc. [ ZNTL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ James B. Bucher, attorney-in-fact for Shannon Campbell	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)